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Discussion
Dr Michael Mack (Dallas, Tex). A paper presented at the Southern
Thoracic Surgical Association meeting last year analyzed the
PREVENT IV trial for graft patency and found that endoscopic
vein harvest was a risk factor for lower graft patency. I think there
is some evidence that this may have some clinical impact, and you
may have defined the mechanism.
It is always said to be dangerous to go home after a medical
meeting because people change their practices based on what they
heard at the meeting. On the basis of your presentation, I think I would
seriously consider earlier heparinization in patients. Have you seen
any adverse clinical sequelae from earlier heparinization, such as late
complications or hematoma of the harvest tunnel?
Dr Brown. We have not seen any complications such as those.
Increased bleeding is an obvious concern with preheparinization
and seems to be one of the reasons that people are reluctant to use
it. However, we found no effect of preheparinization on intraop-
erative blood loss volume or perioperative and postoperative trans-
fusion requirements. The only potential complication we noted
was that the surgical field was not quite as dry. There was some
increased oozing of blood during harvest of the internal thoracic
artery.
Dr Valavanur Subramanian (New York, NY). I have two
questions. Did you determine the age of the clot or the type of the
clot in the SVGs? That would be very important for us.
Dr Brown. We are currently trying to assess the morphology of
this intraluminal clot. One intervention that we have also tried is using
tissue plasminogen activator to lyse this clot, but this strategy has not
proved very effective at decreasing clot volume. We have previously
documented that this intraluminal clot contains platelets, which may
be contributing to the failure of lysis we are observing. Therefore, we
believe our tissue plasminogen activator incubation solution might
benefit from the incorporation of a glycoprotein IIb/IIIa inhibitor.
Obviously, determining the exact morphology of this intraluminal
thrombus would be important in this effort.
Dr Subramanian. The second question concerns infusion of
heparin through the cut end of the vein graft before you do the
EVH. Would that be helpful rather than 5000 units?
Dr Brown. That is something we have also considered. The
problem we encountered with the strategy you describe was that
the vein harvester did not want to be committed to using that
particular section of the vein. However, some other people have
also suggested that technique, and it really just depends on whether
the surgeon is comfortable doing that.
Dr A. W. Atkinson (Raleigh, NC). I think it is a wonderful
study. Interestingly, in our community we have two hospitals and
we have two different techniques for harvesting vein: one is an
open system, I believe the Ethicon system, and the other is a closed
system with CO2 pressure. When we go from one hospital to the
other, we obviously see more overt and after we harvest the vein
we see more interluminal thrombus. We have actually started
giving preharvest heparin in small doses. It is not a scientific study
at all, but observationally we saw a marked decrease in interlumi-
nal thrombus. We are doing the study in a sense just from one
hospital to the other. I really commend you on documenting this
observation that we have seen.
I had the same thought as Dr Subramanian. Why don’t we just
make a small incision at the ankle and flush it with heparinized
saline before harvesting to obviate both problems? I think we may
start to do that until we get it further documented. However, it is
a wonderful study with a new technology that we should look at
with other aspects of vein harvesting.
Do you have any way to identify vein trauma with this tech-
nology or some other technology about intimal damage? It defi-
nitely occurs differently with different techniques.
Dr Brown. Thank you. I realize other surgeons have already
begun giving heparin before EVH, and I think one of the
exciting things about OCT is that it has now allowed us to truly
quantitate the efficacy of this strategy for reducing intraluminal
clot burden.
OCT is also very sensitive for detecting intimal damage. It
obviously has much higher resolution than intravascular ultra-
sound, and we are currently using it to determine conduit quality
intraoperatively, especially in regard to harvesting—related
trauma. Here you can see an intimal tear, and we normally see this
occur just around branch points. We also use OCT to evaluate
radial arteries, and in those vessels we see some more overt trauma
than in the SV, probably owing to the more friable nature of the
radial.
Dr Atkinson. Do you have further studies planned comparing
harvesting techniques with intimal damage?
Dr Brown. We are conducting studies like this with the radial
artery. However, it should be noted that we do not see harvesting-
related trauma very often in the SV after EVH, so our current trials
are assessing only the radial artery.
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